Drug Profile
Methylphenidate sustained release - DURECT Corporation
Alternative Names: Methydur; Methydur sustained release capsules; ORADUR-ADHD; ORADUR-Methylphenidate; ORADUR®-Methylphenidate ERLatest Information Update: 26 Nov 2021
Price :
$50
*
At a glance
- Originator DURECT Corporation
- Developer DURECT Corporation; Orient Pharma
- Class Behavioural disorder therapies; Neuroprotectants; Nootropics; Phenylacetates; Piperidines; Sleep disorder therapies; Small molecules
- Mechanism of Action Adrenergic receptor modulators; Central nervous system stimulants; Dopamine release stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Attention-deficit hyperactivity disorder; Attention-deficit hyperactivity disorder
Highest Development Phases
- Marketed Attention-deficit hyperactivity disorder
Most Recent Events
- 30 Sep 2020 Launched for Attention-deficit hyperactivity disorder (In adolescents, In children) in Taiwan (PO)
- 18 Sep 2018 Orient Pharma intends to launch ORADUR-methylphenidate extended-release capsule for Attention deficit hyperactivity disorder in Taiwan in 2019
- 18 Sep 2018 Methylphenidate sustained release - DURECT Corporation is available for licensing in Asia, Pacific Rim countries (excluding Europe, Japan, North America) as of 18 Sep 2018. http://www.oppharma.com/index.php/eng/index